ReviewFrontiers in oncology2022

Rationale for combination of paclitaxel and CDK4/6 inhibitor in ovarian cancer therapy - non-mitotic mechanisms of paclitaxel.

Elizabeth R Smith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.